New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
16:06 EDTLLY, INCYEli Lilly, Incyte announce additional Phase IIb baricitinib data
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase inhibitor, in patients with moderate-to-severe rheumatoid arthritis who had an inadequate response to treatment with methotrexate. Additionally, Magnetic Resonance Imaging technology was used in a sub-study to examine the effect of baricitinib on joint erosion and other markers of structural changes in and around the joint. Positive results of the placebo-controlled 12-week portion of the study were presented at the European League Against Rheumatism's Annual European Congress of Rheumatology in June. Patients taking baricitinib 4 mg or 8 mg once daily reported significant differences in ACR20, ACR50 and ACR70 responses compared with patients taking placebo. Data from the 12- to 24-week portion of the study, which did not include a placebo control, showed that patients who continued to receive 2 mg, 4 mg or 8 mg baricitinib once daily doses maintained or improved ACR20, ACR50 and ACR70 responses. The study also included a large sub-study of 154 patients using Magnetic Resonance Imaging to examine the effect of different doses of baricitinib on joint changes in a subgroup of patients with erosive RA and inadequate response to treatment with methotrexate. There was statistically significant improvement in both the Total Inflammation Score and the Total Joint Damage Score for both 4 mg and 8 mg baricitinib doses compared with placebo at 12 weeks. The effects persisted through 24 weeks.
News For LLY;INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
August 23, 2015
12:35 EDTINCYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:55 EDTINCYIncyte management to meet with JPMorgan
Subscribe for More Information
August 20, 2015
13:26 EDTLLYOn The Fly: Top stock stories at midday
Subscribe for More Information
11:33 EDTLLYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
07:37 EDTLLYEli Lilly's Jardiance for diabetes meets primary endpoint in clinical trial
Subscribe for More Information
August 18, 2015
10:01 EDTLLYEli Lilly says Humalog 200 units/mL KwikPen available in U.S. pharmacies
Subscribe for More Information
08:41 EDTINCYIncyte shares poised to advance further, says Argus
Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.
August 17, 2015
14:11 EDTINCYIncyte reveals favorable early data on IDO inhibitor, says Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use